Notable Analyst Rating Changes 2/29: (KERX) (TPH) (RSPP) Upgraded; (DDS) (SWN) (NTI) Downgraded
Tweet Send to a Friend
UPGRADES
FBR Capital upgrades Keryx Biopharmaceuticals (Nasdaq: KERX) from Market Perform to Outperform with a price target of $10 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
FBR Capital upgrades Keryx Biopharmaceuticals (Nasdaq: KERX) from Market Perform to Outperform with a price target of $10 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
